Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.34 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10840787 | 0.80 | AR (0.43) | ARPNMTMEN1HSPA1AHSPA8 | |
| SCHEMBL10841335 | 0.77 | AHR (0.37) | ARPNMTMTNR1AHTR2CHTR2B | |
| SCHEMBL1735444 | 0.71 | AR (0.40) | ARPNMTMEN1HSPA1AHSPA8 | |
| SCHEMBL1735572 | 0.71 | CES1 (0.43) | ARMEN1KMT2APARP1HTR2A | |
| SCHEMBL20870486 | 0.69 | MTNR1A (0.60) | ARMTNR1A | |
| SCHEMBL29659962 | 0.69 | MTNR1A (0.60) | ARMTNR1A | |
| SCHEMBL29659944 | 0.69 | MTNR1A (0.60) | ARMTNR1A | |
| SCHEMBL22262591 | 0.69 | MTNR1A (0.60) | ARMTNR1A | |
| SCHEMBL4139663 | 0.69 | MTNR1A (0.60) | ARMTNR1A | |
| SCHEMBL10840792 | 0.69 | KDM4E (0.39) | ARPNMTMTNR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188307-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL COPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | AADAT, KMO, ALDH7A1 | AR 1547/4885PNMT 1061/4885SLC6A2 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.